These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27031651)

  • 1. Designing biomedical proteomics experiments: state-of-the-art and future perspectives.
    Maes E; Kelchtermans P; Bittremieux W; De Grave K; Degroeve S; Hooyberghs J; Mertens I; Baggerman G; Ramon J; Laukens K; Martens L; Valkenborg D
    Expert Rev Proteomics; 2016 May; 13(5):495-511. PubMed ID: 27031651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical design of quantitative mass spectrometry-based proteomic experiments.
    Oberg AL; Vitek O
    J Proteome Res; 2009 May; 8(5):2144-56. PubMed ID: 19222236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted and Untargeted Proteomics Approaches in Biomarker Development.
    Sobsey CA; Ibrahim S; Richard VR; Gaspar V; Mitsa G; Lacasse V; Zahedi RP; Batist G; Borchers CH
    Proteomics; 2020 May; 20(9):e1900029. PubMed ID: 31729135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in mass spectrometry proteomics for biomedical research.
    Li X; Wang W; Chen J
    Sci China Life Sci; 2017 Oct; 60(10):1093-1113. PubMed ID: 29039124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations).
    Hernández B; Parnell A; Pennington SR
    Proteomics; 2014 Jul; 14(13-14):1587-92. PubMed ID: 24737731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental Design in Quantitative Proteomics.
    Burzykowski T; Claesen J; Valkenborg D
    Methods Mol Biol; 2019; 1977():181-197. PubMed ID: 30980329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical design of experiments as a tool in mass spectrometry.
    Riter LS; Vitek O; Gooding KM; Hodge BD; Julian RK
    J Mass Spectrom; 2005 May; 40(5):565-79. PubMed ID: 15880604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Trends and Future Perspectives of State-of-the-Art Proteomics Technologies Applied to Cardiovascular Disease Research.
    Singh SA; Aikawa E; Aikawa M
    Circ J; 2016 Jul; 80(8):1674-83. PubMed ID: 27430298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of LC/MS to proteomics studies: current status and future prospects.
    Chen G; Pramanik BN
    Drug Discov Today; 2009 May; 14(9-10):465-71. PubMed ID: 19429505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of experimental design best practices for proteomics based biomarker discovery: focus on SELDI-TOF.
    Caffrey RE
    Methods Mol Biol; 2010; 641():167-83. PubMed ID: 20407947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum.
    Lopez MF; Kuppusamy R; Sarracino DA; Prakash A; Athanas M; Krastins B; Rezai T; Sutton JN; Peterman S; Nicolaides K
    J Proteome Res; 2011 Jan; 10(1):133-42. PubMed ID: 20499897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multi-model statistical approach for proteomic spectral count quantitation.
    Branson OE; Freitas MA
    J Proteomics; 2016 Jul; 144():23-32. PubMed ID: 27260494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility, limitations, and promise of proteomics in animal science.
    Lippolis JD; Reinhardt TA
    Vet Immunol Immunopathol; 2010 Dec; 138(4):241-51. PubMed ID: 21074277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
    Findeisen P; Neumaier M
    Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pitfalls of proteomics experiments without the correct use of bioinformatics tools.
    Biron DG; Brun C; Lefevre T; Lebarbenchon C; Loxdale HD; Chevenet F; Brizard JP; Thomas F
    Proteomics; 2006 Oct; 6(20):5577-96. PubMed ID: 16991202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mass spectrometry-based proteomic quest for diabetes biomarkers.
    Shao S; Guo T; Aebersold R
    Biochim Biophys Acta; 2015 Jun; 1854(6):519-27. PubMed ID: 25556002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opportunities for nanotechnology-based innovation in tissue proteomics.
    Geho DH; Lahar N; Ferrari M; Petricoin EF; Liotta LA
    Biomed Microdevices; 2004 Sep; 6(3):231-9. PubMed ID: 15377833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating clinical proteomics: the importance of study design.
    Maes E; Cho WC; Baggerman G
    Expert Rev Proteomics; 2015 Jun; 12(3):217-9. PubMed ID: 25925311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker discovery: success as a function of risk mitigation.
    Weiser S
    Scand J Clin Lab Invest Suppl; 2016; 245():S12-6. PubMed ID: 27426622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the organismal scope of proteomics: cross-species protein identification by mass spectrometry and its implications.
    Liska AJ; Shevchenko A
    Proteomics; 2003 Jan; 3(1):19-28. PubMed ID: 12548630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.